Cardax Inc · OTC:CDXI
Cardax — Koffee Korner — Investor Presentation (December 2013)
21 slides from Cardax's investor presentation, Dec 16, 2013
Slide 1: Focusing on the source of inflammation – Investor Presentation
focusing on the source of inflammation 1 Investor Presentation TM
Slide 2: Investment Highlights
• C ardax is developing safe and effective oral anti - inflammatory products addressing multi - billion dollar chronic disease markets • Well positioned to capitalize on the large growth market for astaxanthin nutraceutical/pharmaceutical products • World - class manufacturing, distribution, and mar
Slide 3: Familiar diseases share a common cause: inflammation
Familiar diseases share a common cause INFLAMMATION • Osteoarthritis, RA, IBD, psoriasis • Dyslipidemia • Diabetes, Metabolic Syndrome • Liver Disease ( ASH/ NASH) • Thrombosis/Rethrombosis/CVD • Alzheimer ’ s, Neurodegeneration • Retinal Disease (AMD, Stargardt) • Prostatitis, Prostate Cancer WHY I
Slide 4: What is the source of inflammation?
• Excess oxidative stress inside cells at the mitochondrial level — which can be caused by many factors including, but not limited to, aging, obesity, and smoking — leads to the chronic and dysfunctional activation of cell - signaling pathways that produce inflammation . • Chronic inflammation in va
Slide 5: Astaxanthin: Powerful, Safe Anti-Inflammatory Treatment
Astaxanthin Powerful, Safe Anti - Inflammatory Treatment 5 Astaxanthin is a naturally occurring marine compound that, as described in greater detail in this presentation, is proven to reduce inflammation at its source, without the harmful side effects that are common with other anti - inflammatory p
Slide 6: Role of astaxanthin in various species
Role of astaxanthin (ASTX) in various species ASTX makes salmon red, stronger, more resistant to infections, and increases fish reproduction Synthesized by microalgae (Haematococcus pluvialis), it protects the algae from environmental stress Krill eat microalgae and, in turn, are eaten by salmon and
Slide 7: Without Astaxanthin
Salmon would be weaker and lack their color Lobsters would not be red The observations of the critical importance of astaxanthin in nature have led to more extensive research by the scientific community. WITHOUT ASTAXANTHIN 7
Slide 8: Astaxanthin – Powerful Anti-Inflammatory
• M ore than 1,000 peer reviewed papers about astaxanthin have been published. More than 50 of these peer reviewed papers have been published by Cardax team members and collaborators , including 10 papers published by The American Journal of Cardiology. • There have been more than 27 human proof of
Slide 9: Astaxanthin reduces TNF-α in inflammatory animal model
ASTAXANTHIN REDUCES TNF – α IN INFLAMMATORY ANIMAL MODEL 9 “AX” “AX” “AX” “P” Astaxanthin efficacy Ohgami et al., Ophth. Invest. Vis. Sci. 44(6):2694 - 2701, 2003 More Less
Slide 10: Astaxanthin in Key Human Trials
Astaxanthin in Key Human Trials Reduces : TNF - a , Triglycerides, LDL - C Increases : Adiponectin, HDL - C We provide additional summaries of certain human clinical studies that were published in peer reviewed papers on the following pages 10
Slide 11: Astaxanthin reduces inflammation (TNF-α) in humans
• 17 subjects at risk for metabolic syndrome (ages 22 - 65) must have: – Waist circumference (>85cm) and one of the following: • Fasting plasma glucose >100mg/dL • Triglyceride level >150mg/dL • HDL cholesterol <40mg/dL • Blood pressure >135/85mmHg • 12 weeks; 16mg daily of nutra astaxanthin (as fat
Slide 12: Clinical efficacy of astaxanthin in metabolic syndrome
• 61 subjects at risk for metabolic syndrome (ages 25 - 60): – Fasting triglyceride level 120 - 200mg/dL (normal to borderline high risk) • Double - blind, placebo - controlled study • 12 weeks; 0, 6, 12, or 18 mg daily of astaxanthin • Measures: lipid profiles, inflammatory marker adiponectin • Res
Slide 13: Clinical efficacy of astaxanthin in obese patients
• 27 obese subjects (ages 20 - 55): • BMI > 25 (excluding diabetes, hypertension, cardio disease) • Double - blind, placebo - controlled study • 12 weeks; 20 mg daily of astaxanthin • Measures: lipid profiles and oxidative stress • Results: – LDL - C significantly decreased ( - 10.4%) – HDL - C non
Slide 14: Rationale for astaxanthin in osteoarthritis
• Current Treatment for OA – Anti - inflammatories – NSAIDS (Celebrex, Alleve, etc.) – Steroids (Prednisolone, etc.) – Glucosamine/Chondroitin • Astaxanthin as an Anti - Inflammatory – TNF - α reduction in animals = predinisolone – TNF - α reduction confirmed in humans – Impact on COX - 2, PGE 2, IL
Slide 15: Astaxanthin does not have the side effects of certain other treatments
* in relevant animal models ASTAXANTHIN DOES NOT HAVE THE SIDE EFFECTS OF CERTAIN OTHER ANTI - INFLAMMATORY / PAIN RELIEF TREATMENTS 15 Possible Side Effects of the Other Anti - Inflammatory / Pain Relief Drugs Benefits of Astaxanthin Infections (steroids/anti - TNFs) Reduces infections* Cardiovascu
Slide 16: Scientific results = market explosion
• Sales of astaxanthin products by a leading producer have increased over 100% over past 3 years • Resounding recommendation from Dr. Oz • Supply shortages have impacted astaxanthin market • The Cardax Opportunity SCIENTIFIC RESULTS = MARKET EXPLOSION 16
Slide 17: Current astaxanthin production issues
Current Microalgal Astaxanthin Production is Agricultural which has certain issues • Cannot accommodate demand/does not scale • Inefficient and costly for mass production • Astaxanthin yield variable and at risk (weather, disease) • Requires ideal (tropical) conditions • Optimal dosing impractical (
Slide 18: The Cardax Solution
Cost effective, nature identical Astaxanthin synthetic that can be mass produced and distributed to meet the rapidly growing demand THE CARDAX SOLUTION 18
Slide 19: Pharmaceutical Development
Why seek pharmaceutical status for Astaxanthin? ▪ A credible pharmaceutical program should increase our revenue opportunities and value ▪ ~3 to 5 low risk, low cost, clinical programs planned (assuming additional financing or strategic partnership) ▪ Potential OTC and RX drug approvals ₋ OTC drug ap
Slide 20: Cardax Pipeline
Cardax Lead Product: multiple indications; nutraceutical first, then OTC and Rx development . Initial marketing targets : Lycophyll and related esters Prostate Disease (Prostatitis, Prostate C ancer ) Astaxanthin and related esters ( NASH, ASH) Astaxanthin and related esters Neurological Disease ( A
Slide 21: Focusing on the source of inflammation
focusing on the source of inflammation 21 TM
Koffee Korner — Investor Presentation (December 2013) on 6ix